Company intelligence / Profile preview

Syntis Bio

Boston, Massachusetts, United Statessyntis.bio ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

SYNT-101 has shown promising results in preclinical rodent models with consistent 1% weekly weight loss over a six-week period while preserving 100% of lean muscle mass. In a first-in-human pilot study, an investigational formulation demonstrated evidence of nutrient redirection and satiety hormone modulation with strong safety and tolerability[7].

Therapeutic areas: Metabolic DisordersEndocrinologyGastroenterology
Modalities: Oral therapiesengineered enzymespolymer-based drug delivery
Industry: Biotech

Drug pipeline

9 assets

SYNT-101

8 more assets in the full pipeline.

Request access →

Partnerships

Codexis, Inc. (acquired enzyme portfolio from them in April 2024)

Beyond the preview

Go deeper on Syntis Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syntis Bio.

Explore the full profile